GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx,

Copycat versions of popular drugs like Ozempic and Mounjaro have continued to proliferate in a postshortage era, with some experts saying “regulatory neglect” is allowing for potentially dangerous, unapproved drugs to reach consumers.

The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo.

Ozempic faces over 1,800 lawsuits in US courts, with damages possibly topping $2 billion. Patients allege the drug caused stomach paralysis, vision loss, and other severe complications not clearly warned about.

The Little Mix singer said she auditioned for "The X Factor" just months after leaving the hospital, where she was treated for an eating disorder.

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.

Mounjaro price increases have prompted patients to search for cheaper options, including Wegovy. But is it possible to swap partway through treatment?

The weight loss injectable Ozempic has faced several lawsuits in 2025 from people who had a negative experience with the semaglutide.